Perivision and its software combining artificial intelligence and complex algorithms to carry out vision examinations, Bioscibex and its innovative bioreactor for drug production, and Carewell and its platform connecting the needs of health and care facilities with available qualified personnel. All three received support from FIT via a Tech Growth loan of CHF 300,000, a Tech Seed loan of CHF 100,000 and a Digital Seed loan of CHF 50,000 respectively..

Perivision及其结合人工智能和复杂算法进行视力检查的软件，Bioscibex及其用于药物生产的创新生物反应器，以及Carewell及其将卫生和护理机构需求与可用合格人员相连接的平台。这三家公司分别获得了FIT通过Tech Growth贷款30万瑞士法郎、Tech Seed贷款10万瑞士法郎和Digital Seed贷款5万瑞士法郎的支持。

PeriVision and its innovative headset for eye examinations

PeriVision及其用于眼科检查的创新头戴设备

Faced with the prevalence of eye diseases and their increase due to demographic change, healthcare systems are short of ophthalmologists and optometrists. Most of the problem stems from the vision tests currently in use: multiple tests that require a lot of time (around 15-30 minutes per test) and resources (1 assistant and a dedicated room), are expensive and unreliable, with a margin of error of 10-30%.

面对眼部疾病普遍流行及其因人口结构变化而增加的情况，医疗卫生系统缺乏眼科医生和验光师。目前使用的视力测试是造成这一问题的主要原因：多项测试需要耗费大量时间（每次测试大约需要15-30分钟）和资源（1名助手和一个专用房间），费用昂贵且不可靠，误差幅度达到10-30%。

These inefficiencies result in bottlenecks, with patients losing their ocular vision due to inadequate testing and treatment. .

这些低效率导致了瓶颈，患者因检测和治疗不足而丧失视力。

The software developed by

由以下人员开发的软件

PeriVision

PeriVision

incorporates complex algorithms based on artificial intelligence, making it possible to obtain extremely accurate test results and even to predict future developments. This software is integrated into a virtual reality headset. Thanks to its speed of analysis, ease of use and automated instructions, the PeriVision system is helping to increase the flow of optometry and ophthalmology patients by 30%..

结合了基于人工智能的复杂算法，从而可以获得极其准确的测试结果，甚至预测未来发展。该软件集成在一款虚拟现实头戴设备中。凭借其快速的分析速度、易用性以及自动化的操作指示，PeriVision 系统有助于将视光学和眼科患者的流量增加 30%。

The CHF 300,000 Tech Growth loan granted by FIT will be used by PeriVision to win more customer contracts, as well as to develop and integrate new functionalities into its system (new tests, diagnostics and prognoses algorithms).

FIT 授予 PeriVision 的 30 万瑞士法郎技术成长贷款将用于争取更多客户合同，同时开发和集成新功能到其系统中（新测试、诊断和预测算法）。

Bioscibex and its bioreactor, transforming the way drugs are produced

生物科学公司及其生物反应器，正在改变药物的生产方式

Biomedicines have been shown to be effective in treating a large number of diseases, including autoimmune diseases and cancer. However, their high cost, due to high production costs, is a major barrier to access for many patients. In order to reduce the cost of these treatments, the production process needs to be simplified..

生物药物已被证明在治疗大量疾病方面有效，包括自身免疫性疾病和癌症。然而，由于生产成本高，其高昂的价格成为许多患者获得治疗的主要障碍。为了降低这些治疗的成本，需要简化生产过程。

At present, this process is based on seven consecutive stages that are complex, costly and subject to contamination risks. With its innovative bioreactor, Bioscibex reduces these steps to just two, minimising costs, contamination risks and time. Thanks to a unique combination of two-axis movements, the bioreactor developed by .

目前，该过程基于七个连续的阶段，这些阶段复杂、昂贵且存在污染风险。通过其创新的生物反应器，Bioscibex将这些步骤减少到仅两个，最大限度地降低了成本、污染风险和时间。得益于独特的双轴运动组合，由该公司开发的生物反应器。

Bioscibex

生物科学交易所

offers the widest volume range on the market, enabling cell expansion from 30 mL to 30 L in a single step.

提供市场上最广泛的体积范围，能够单步实现从30毫升到30升的细胞扩增。

With the CHF 100,000 Tech Seed loan received from FIT, Bioscibex will continue to invest in the research and development of its beta prototype for customer testing. This prototype will be ready by mid-2025.

通过从FIT获得的10万瑞士法郎的Tech Seed贷款，Bioscibex将继续投资于其用于客户测试的β原型的研发。该原型将于2025年年中准备就绪。

Carewell and its platform for connecting healthcare establishments with available qualified staff

Carewell及其连接医疗机构与可用合格人员的平台

Switzerland, like many other countries, is facing a shortage of healthcare staff, with almost 12,000 qualified people missing from hospitals and other institutions, and absence rates of around 20%. The good news is that there is a potential untapped reserve: the more than 60,000 people who have left their jobs in healthcare.

瑞士与许多其他国家一样，面临医护人员短缺的问题，医院和其他机构缺少近 12,000 名合格人员，缺勤率约为 20%。好消息是，有一个潜在的未开发储备：超过 60,000 名离职的医疗保健人员。

The problem is that they have no easy way of finding temporary work, because when it comes to replacing people who are absent, establishments often don't have an efficient tool for managing the pool of internal replacements, and services such as temporary employment agencies don't work to their satisfaction.

问题在于他们没有容易找到临时工作的方式，因为当需要替换缺席人员时，企业通常没有高效的工具来管理员工内部替补池，而且像临时就业机构这样的服务也不能让他们满意。

As a result, there is no match between the needs of care structures and the people who can potentially be mobilised to cover them..

因此，护理机构的需求与可能被动员来满足这些需求的人之间不存在匹配。

In light of this observation,

鉴于这一观察，

Carewell

凯尔美德公司

has developed a platform that brings these two areas together and enables their respective needs to converge: managing replacements for healthcare establishments and, for health professionals, to find flexible jobs in the healthcare sector that match their expectations. The innovation rests on three pillars: a digital platform (to post job advertisements, manage files, etc.), an algorithm based on artificial intelligence that matches employers' needs with available profiles, and support activities to retain talent.

开发了一个将这两个领域结合在一起并使它们各自需求交汇的平台：为医疗机构管理人员替换，为医疗专业人员寻找符合他们期望的灵活工作。该创新基于三大支柱：一个数字平台（用于发布招聘广告、管理文件等）、一个基于人工智能匹配雇主需求与可用人才的算法，以及保留人才的支持活动。

These three modules will remove the friction from the recruitment process and help to resolve the shortage..

这三个模块将消除招聘过程中的摩擦，有助于解决人才短缺问题。

After awarding a Digital Grant of CHF 20,000 in 2024, FIT is reiterating its support for Carewell via a Digital Seed loan of CHF 50,000, which will support the next stages in the development of the platform and the costs associated with marketing and recruiting additional freelancers.

2024年，在颁发了20,000瑞士法郎的数字资助后，FIT再次通过提供50,000瑞士法郎的数字种子贷款来支持Carewell，这笔资金将用于支持平台开发的下一阶段以及与营销和招聘更多自由职业者相关的成本。

(Press release)

（新闻稿）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送